Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Holmium laser enucleation of the prostate using Moses 2.0 vs non‐Moses: a randomised controlled trial
Nevo, Amihay , Faraj, Kassem , Cheney, Scott, Stern, Karen , Borofsky, Michael S. , Gnessin, Ehud , Humphreys, Mitchell R. , Faraj, Kassem S , Cheney, Scott M, Moore, Jonathan P, Stern, Karen L, Stern, Karen L , Moore, Jonathan P.

Mayo Clinic

BJU International | December 4, 2020 | Volume: 127 | Issue: 5 | Pages: 553-559

10.1111/bju.15265 | PMID 33025749 Get It

Objectives To compare the enucleation efficiency of Moses 2.0 with non‐Moses technology in patients undergoing holmium laser enucleation of the prostate (HoLEP). Patients and Methods A double‐blinded, randomised study of patients undergoing HoLEP at the Mayo Clinic in Arizona, using the Lumenis Pulse™ 120H laser system. Patients were randomised to either right lobe enucleation using Moses 2.0 and left lobe enucleation using non‐Moses, or the opposite. The primary outcome was individual lobe enucleation efficiency. Secondary outcomes included individual lobe laser time, laser energy, individual enucleation and haemostasis laser energies, and fibre burn back. Two independent reviewers watched videos of the procedures and provided a subjective evaluation of the technologies. Results A total of 27 patients were included in the study. For the entire cohort, Moses 2.0 had less fibre degradation (3.5 vs 16.8 mm, P < 0.01) compared to non‐Moses. When HoLEP procedures were performed by an expert, Moses 2.0 resulted in shorter enucleation time (21 vs 36.7 min, P = 0.016) and higher enucleation efficiency (1.75 vs 1.05 g/min, P = 0.05) compared to non‐Moses. When HoLEP was performed by trainees, the Moses 2.0 cohort had a shorter haemostasis laser time (4.1 vs 9 min, P = 0.035) compared to the non‐Moses. Fibre degradation was lower with Moses 2.0 compared to non‐Moses for both experts and trainees. Moses 2.0 received a higher score than the standard technology for the incision sharpness, fibre control, tissue separation, tissue damage, haemostasis, visibility, and charring. The overall inter‐observer correlation coefficient was 0.63. Conclusion Moses 2.0 has higher enucleation efficiency compared to non‐Moses when used by experts. The subjective evaluation favoured Moses 2.0.
Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype
Buciuc, Marina , Whitwell, Jennifer L. , Kasanuki, Koji , Graff‐Radford, Jonathan , Lowe, Val J. , Graff‐Radford, Neill R. , Rush, Beth , Franczak, Malgorzata, Flanagan, Margaret E. , Rademakers, Rosa , Ross, Owen A. , Parisi, Joseph E., Reichard, R. Ross , Bigio, Eileen H. , Josephs, Keith A. , Strand, Edythe A. , Baker, Matthew C, Ross, Owen A , Dickson, Dennis W , Josephs, Keith A , Buciuc, Marina , Machulda, Mary M. , Duffy, Joseph R. , Baker, Matthew , Ghetti, Bernardino , Raghunathan, Aditya , Dickson, Dennis W. , Flanagan, Margaret E

Mayo Clinic

Annals of Neurology | December 4, 2020 | Volume: 89 | Issue: 3 | Pages: 520-533

10.1002/ana.25979 | PMID 33274526 Get It

ObjectiveThe objective of this study was to describe clinical features, [18F]‐fluorodeoxyglucose (FDG)‐positron emission tomography (PET) metabolism and digital pathology in patients with logopenic progressive aphasia (LPA) and pathologic diagnosis of diffuse Lewy body disease (DLBD) and compare to patients with LPA with other pathologies, as well as patients with classical features of probable dementia with Lewy bodies (pDLB).MethodsThis is a clinicopathologic case‐control study of 45 patients, including 20 prospectively recruited patients with LPA among whom 6 were diagnosed with LPA‐DLBD. We analyzed clinical features and compared FDG‐PET metabolism in LPA‐DLBD to an independent group of patients with clinical pDLB and regional α‐synuclein burden on digital pathology to a second independent group of autopsied patients with DLBD pathology and antemortem pDLB (DLB‐DLBD).ResultsAll patients with LPA‐DLBD were men. Neurological, speech, and neuropsychological characteristics were similar across LPA‐DLBD, LPA‐Alzheimer's disease (LPA‐AD), and LPA‐frontotemporal lobar degeneration (LPA‐FTLD). Genetic screening of AD, DLBD, and FTLD linked genes were negative with the exception of APOE ε4 allele present in 83% of LPA‐DLBD patients. Seventy‐five percent of the patients with LPA‐DLBD showed a parietal‐dominant pattern of hy pometabolism; LPA‐FTLD – temporal‐dominant pattern, whereas LPA‐AD showed heterogeneous patterns of hypometabolism. LPA‐DLBD had more asymmetrical hypometabolism affecting frontal lobes, with relatively spared occipital lobe in the nondominantly affected hemisphere, compared to pDLB. LPA‐DLBD had minimal atrophy on gross brain examination, higher cortical Lewy body counts, and higher α‐synuclein burden in the middle frontal and inferior parietal cortices compared to DLB‐DLBD.InterpretationWhereas AD is the most frequent underlying pathology of LPA, DLBD can also be present and may contribute to the LPA phenotype possibly due to α‐synuclein‐associated functional impairment of the dominant parietal lobe. ANN NEUROL 2021;89:520–533
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
Chi, Andrew , Kurz, Sylvia C. , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , DeGroot, John, Hall, Matthew D. , Daghistani, Doured , Schwartz, Jonathan , Cartaxo, Rodrigo T. , Siada, Ruby , Miklja, Zachary , Bruzek, Amy K., Wierzbicki, Kyle , Paul, Alyssa , Wolfe, Ian, Leaoard, Marcia, Garton, Hugh , Mody, Rajen , Robertson, Patricia L. , Merdinger, Krystal, Venneti, Sriram , Oster, Wolfgang, Allen, Joshua E. , Kawakibi, Abed Rahman , Tarapore, Rohinton S. , Gardner, Sharon L , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Harrison, Rebecca A , Mehta, Minesh P. , Odia, Yazmín , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Umemura, Yoshie , Yadav, Viveka Nand , Cantor, Evan , Lu, Guangrong , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii347-iii347

10.1093/neuonc/noaa222.305 Get It

Abstract ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has shown encouraging efficacy in H3 K27M-mutant glioma. Given that the thalamus has the highest extra-striatal expression of DRD2, we performed an integrated preclinical and clinical analysis of ONC201 in thalamic H3 K27M-mutant glioma. ONC201 was effective in mouse intra-uterine electroporation (IUE)-generated H3 K27M-mutant gliomas, with an in vitro IC50 of 500 nM and 50% prolongation of median survival in vivo (p=0.02, n=14). We analyzed thalamic H3 K27M-mutant glioma patients treated with ONC201 on active clinical trials as of 5/22/19 enrollment (n=19 recurrent and 10 post-radiation, non-recurrent; 5–70 years old). As of 12/18/2019, PFS6 and OS12 are 26.3% and 36.8%, respectively, in the recurrent group. For non-recurrent patients, with median follow up of 21.9 months (8.6–26.6) from diagnosis, median PFS or OS have not been reached. This surpasses historical OS of 13.5 months. Best response by RANO includes 1 CR, 3 PR, 4 SD, 8 PD for recurrent patients and 2 PR, 4 SD, 1 PD for non-recurrent patients (4 on-trial patients experienced regressions that are yet unconfirmed responses). Median duration of response for recurrent patients is 14.0 months (2.0–33.1). Furthermore, H3 K27M cell-free tumor DNA in plasma and CSF correlated with MRI response. In summary, single agent ONC201 administered at recurrence, or adjuvantly following radiation, demonstrates promising clinical efficacy in thalamic H3 K27M-mutant glioma patients who currently have no effective treatments following radiation. Investigations are ongoing to assess whether micro-environmental DRD2 expression explains the early exceptional responses in thalamic H3 K27M-mutant glioma.
EXTH-12. INHIBITION OF CBP/p300 HISTONE ACETYLATION ACTIVITY ENHANCES TEMOZOLOMIDE ACTIVITY IN GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS
Kitange, Gaspar J. , Hu, Zeng, Carlson, Brett L. , Wilson, Jonathan E. , Bommi‐Reddy, Archana, Conery, Andy, Burgenske, Danielle M. , Bakken, Katrina K. , He, Lihong , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii89-ii89

10.1093/neuonc/noaa215.366 Get It

Abstract There is an unmet need to identify novel targets that can sensitize temozolomide (TMZ) or prevent resistance in GBM. We have demonstrated that retinoblastoma binding protein 4 (RBBP4) interacts with p300 to modulate expression of genes involved in homologous recombination (HR), including RAD51. In vitro, RBBP4- or p300-shRNA significantly sensitized TMZ in patient derived xenograft (PDX) GBM43 cells (relative fluorescence for 100µM TMZ treated control shNT cells was 0.89 ± 0.1 vs 0.47± 0.09 and 0.39 ± 0.01 for shRBBP4 and shp300, respectively (p&lt; 0.01)). TMZ sensitization increased DNA damage signaling through phosphorylation of KAP1 (p-KAP1) and p-CHK1. Moreover, RBBP4- or p300-shRNA delayed the repair of TMZ-induced DSBs evidenced by persistent gH2AX. Silencing RBBP4 or p300 reduced acetylation of lysine 27 of histone H3 (H3K27Ac) within promoters of HR genes regulated by RBBP4/p300 complex. Thus, RBBP4/p300 complex controls gene expression through p300-mediated histone acetyltransferase (HAT) activity, suggesting that p300 inhibitors could sensitize GBM to TMZ. Accordingly, CBP/p300 inhibitor CPI1612 significantly suppressed H3K27Ac and HR repair genes, including RAD51. Moreover, CPI1612 sensitized TMZ in GBM43 (synergy score = 258), and TMZ/CPI1612 significantly suppressed growth of GBM39 PDX cells compared with either drug alone (confluence (%) was 92 ± 1.0 (DMSO), 76.5 ± 4.6 (10 µM TMZ), 62 ± 3.4 (10 nM CPI1612) and 21.9 ± 3.2 (TMZ 10 µM/CPI-CPI1612 10 nM). CPI1612 enhanced TMZ-induced DSBs with increased damage signaling through p- KAP1 and persistent gH2AX. Pharmacodynamics studies in GBM39 orthotopic mice models revealed that oral CPI1612 penetrates the brain and accumulate in tumor regions and suppresses H3K27Ac without significant weight loss in mice that received placebo, TMZ, CPI1612 alone or combined TMZ/CPI-1612, demonstrating good animal tolerability. Collectively, these findings are encouraging that CBP/p300 inhibition by the brain penetrant CPI-1612 is a potential strategy for enhancing the efficacy of TMZ in GBM.
EPEN-35. PERITONEAL CARCINOMATOSIS OF ANAPLASTIC EPENDYMOMA: FIRST REPORTED CASE
Schwartz, Jonathan , Weinmann, Dena, Guerin, Julia M. , Eckel, Laurence J. , Gesina, Keating, Guerin, Julia, Daniels, David J.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii315-iii315

10.1093/neuonc/noaa222.170 Get It

Abstract Peritoneal Carcinomatosis of anaplastic ependymoma is not a previously reported entity. The authors report on a child with multiple successfully treated brain and spine disease occurrences who subsequently develops carcinomatosis of the abdomen and no evidence of CNS recurrence. Ependymoma accounts for up to 10% of childhood CNS tumors diagnosed in the United States with a median age of 51–71 months. Typical locations are based on age. Disease is typically treated with surgical resection followed by radiation. The role of chemotherapy has not been proven but currently being examined with open clinical trials. We will describe patient’s presentations, clinical treatment and recurrence with subsequent treatment and outcome at time of meeting.
Humeral stress shielding following cemented endoprosthetic reconstruction: An under‐reported complication?
Braig, Zachary V. , Tagliero, Adam J. , Rose, Peter S. , Elhassan, Bassem T. , Houdek, Matthew T. , Barlow, Jonathan D. , Sanchez-Sotelo, Joaquin, Houdek, Matthew T , Tagliero, Adam , Wagner, Eric R. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Surgical Oncology | December 1, 2020 | Volume: 123 | Issue: 2 | Pages: 505-509

10.1002/jso.26300 | PMID 33259663 Get It

AbstractIntroductionThe proximal humerus is a common location for primary and non‐primary tumors. Reconstruction of the proximal humerus is commonly performed with an endoprosthesis with low rates of structural failure. The incidence and risk factors for stress shielding are under reported.MethodsThirty‐nine (19 male, 20 female) patients underwent resection of the proximal humerus and reconstruction with a cemented modular endoprosthesis between 2000 and 2018. The mean resection length was 12 ± 4 cm and was most commonly performed for metastatic disease (n = 26, 67%).ResultsStress shielding was observed in 9 (23%) patients at a mean of 29 (6–132) months postoperatively. Patients with stress shielding were noted to have shorter intramedullary stem length (87 vs. 107 mm, p < .001), longer extramedullary implant length (16 vs. 14 cm, p = .01) and a higher extramedullary implant to stem length ratio (2.1 vs. 1.1, p < .001). The incidence of stress shielding was higher (p = .003) in patients reconstructed with 75 mm stem (n = 6, 67%) lengths.ConclusionStress shielding of the humerus was associated with the use of shorter stems and long extramedullary implants. The long‐term ramifications of stress shielding on implant stability, complications at the time of revision surgery, and overall patient outcomes remain unknown.
Impact of treatment strategies for AF on the progression and regression of AF type in the CABANA trial
Packer, Danielle, Monahan, Kristi H. , Piccini, Jonathan P. , Al‐Khalidi, Hussein R. , Poole, Jeanne E. , Bahnson, Tristram D. , Silverstein, A , Mark, Daniel B.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.0680 Get It

Abstract Background The CABANA trial compared drug vs ablation therapy yet did not identify a difference in the primary endpoint of death, stroke, severe bleeding, or cardiac arrest or the secondary endpoint of all-cause mortality by intention to treat (ITT) analysis. Nevertheless, there was evidence of improved outcomes and survival in the as-treated and per-protocol analyses. Objectives To determine how the treatment strategies of drug therapy vs ablation impact the atrial fibrillation progression and regression. Methods CABANA randomized 2204 pts with AF ≥65 yrs old or &lt;65 with ≥1 risk factor for stroke at 126 sites worldwide to ablation with pulmonary vein isolation vs drug including rate/rhythm control medication. AF type was recorded at the time of enrollment in the CABANA Trial. Following treatment with drug therapy or ablation, the AF type was assessed as recorded at the patient's last follow-up. Comparisons between baseline AF type and last AF type were performed according to ITT. Results Following treatment with ablation, 64% maintained sinus rhythm with elimination of AF, 11% experienced AF regression, and only 7% had progression of AF. In contrast, in those randomized to drug therapy, only 48% experienced maintenance of sinus rhythm, 10% experienced AF regression, and 13% had progression of AF. Moreover, in the drug arm there was a 32% increase in long-standing persistent compared with a 49% reduction in the ablation arm. Conclusion Catheter ablation significantly alters the natural history of atrial fibrillation. Intention to treat analysis reveals that catheter ablation provides superior elimination of AF, protection against AF progression, and dramatically lower risks of long-standing persistent AF. Figure 1 Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): National Institutes of Health
Automated CT Analysis of Major Forms of Interstitial Lung Disease
Crews, Marlee S. , Bartholmai, Brian J. , Adegunsoye, Ayodeji , Montner, Steven M. , Karwoski, Ronald A., Husain, Aliya N. , Vij, Rekha, Noth, Imre , Strek, Mary E. , Bartholmai, Brian J , Oldham, Justin M , Chung, Jonathan Hero

Mayo Clinic

Journal of Clinical Medicine | November 23, 2020 | Volume: 9 | Issue: 11 | Pages: 3776

10.3390/jcm9113776 | PMID 33238466 Get It

This study aimed to determine diagnostic and prognostic differences in major forms of interstitial lung disease using quantitative CT imaging. A retrospective study of 225 subjects with a multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with autoimmune features (IPAF), connective tissue disease (CTD), or chronic hypersensitivity pneumonitis (cHP) was conducted. Non-contrast CT scans were analyzed using the Computer Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) program. Resulting data were analyzed statistically using ANOVA and Student’s t-test. Univariate, multivariable, and receiver operating characteristic analyses were conducted on patient mortality data. CALIPER analysis of axial distribution on CT scans in those with IPF demonstrated greater peripheral volumes of reticulation than either CTD (p = 0.033) or cHP (p = 0.007). CTD showed lower peripheral ground-glass opacity than IPF (p = 0.005) and IPAF (p = 0.004). Statistical analysis of zonal distributions revealed reduced lower zone ground-glass opacity in cHP than IPF (p = 0.044) or IPAF (p = 0.018). Analysis of pulmonary vascular-related structure (VRS) volume by diagnosis indicated greater VRS volume in IPF compared to CTD (p = 0.003) and cHP (p = 0.003) as well as in IPAF compared to CTD (p = 0.007) and cHP (p = 0.007). Increased reticulation (p = 0.043) and ground glass opacity (p = 0.032) were predictive of mortality on univariate analysis. Increased pulmonary VRS volume was predictive of mortality (p < 0.001) even after multivariate analysis (p = 0.041). Quantitative CT imaging revealed significant differences between ILD diagnoses in specific CT findings in axial and, to a lesser degree, zonal distributions. Increased pulmonary VRS volume seems to be associated with both diagnosis and survival.
Platelet transfusion is associated with 90‐day and 1‐year mortality for adult patients requiring veno‐arterial extracorporeal membrane oxygenation
Esper, Stephen A. , Wallisch, William John , Ryan, John P. , Sánchez, Pablo Menéndez , Sciortino, Christopher M., Murray, Holt , Arlia, Peter, D’Cunha, Jonathan, Mahajan, Aman , Triulzi, Darrell J., Esper, S A , Sanchez, Pablo, Subramaniam, Kathirvel

Mayo Clinic

Vox Sanguinis | November 20, 2020 | Volume: 116 | Issue: 4 | Pages: 440-450

10.1111/vox.13016 | PMID 33215723 Get It

BackgroundStudies examining one‐year mortality respecting component blood transfusion are sparse. We hypothesize that component blood product transfusions are negatively associated with 90‐day and 1‐year survival for all patients requiring veno‐arterial (VA) or veno‐venous (VV) ECMO.Study Design and MethodsThis was an IRB‐approved retrospective cohort analysis of 676 consecutive patients requiring ECMO at the University of Pittsburgh between 2005 and 2016. Patients were analysed both as an entire cohort and as two subsets with respect to ECMO modality (VA vs. VV). Additional data collected and analysed included patient characteristics, laboratory values and blood product transfusion.ResultsMultivariable analysis revealed that platelet transfusion was associated with 90‐day mortality (OR: 1·05, P = 0·037) and one‐year mortality for the entire cohort (OR = 1·05, P = 0·046,). Platelet transfusion volume was also associated with mortality in the VA‐ECMO subset of patients at both 90 days (OR = 1·08, P = 0·03) and one year (OR: 1·11, P = 0·014). Age, peak International Normalized Raton ECMO, nadir haemoglobin (on ECMO) and final haemoglobin (after ECMO) were significantly associated with mortality for patients requiring VA‐ECMO. For VV‐ECMO patients, age, INR and peak creatinine on ECMO were associated with mortality. No individual component blood product was associated with one‐year mortality for patients requiring VV‐ECMO.ConclusionPlatelet transfusion was associated with increased 90‐day and 1‐year mortality for patients requiring VA‐ECMO.
Structural Features of Small Molecules Targeting the RNA Repeat Expansion That Causes Genetically Defined ALS/FTD
Ursu, Andrei , Wang, Kye Won , Bush, Jessica A. , Chen, Jonathan L. , Baisden, Jared T. , Zhang, Yong‐Jie , Petrucelli, Leonard , Yildirim, Ilyas , Chen, Jonathan L , Gendron, Tania F. , Yildirim, Ilyas , Disney, Matthew D , Zhang, Yong-Jie , Choudhary, Shruti , Disney, Matthew D.

Mayo Clinic

ACS Chemical Biology | November 16, 2020 | Volume: 15 | Issue: 12 | Pages: 3112-3123

10.1021/acschembio.0c00049 | PMID 33196168 Get It